journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Arthritis and Rheumatism

journal
https://www.readbyqxmd.com/read/29776658/ustekinumab-for-refractory-giant-cell-arteritis-a-prospective-52-week-trial
#1
Richard Conway, Lorraine O'Neill, Phil Gallagher, Geraldine M McCarthy, Conor C Murphy, Douglas J Veale, Ursula Fearon, Eamonn S Molloy
OBJECTIVES: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH 1 and TH 17 responses and are implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA. METHODS: We performed a prospective open label study of ustekinumab in patients with refractory GCA...
April 22, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29773231/biologics-in-sapho-syndrome-a-systematic-review
#2
REVIEW
Dimitrios Daoussis, Georgia Konstantopoulou, Pantelis Kraniotis, Lazaros Sakkas, Stamatis-Nick Liossis
BACKGROUND: The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. METHODS: We present herein a patient with refractory to treatment SAPHO syndrome who exhibited a dramatic and fast response to IL-17 blockade. Additionally, we performed a systematic review of all cases of patients with SAPHO syndrome treated with biologics to date...
April 17, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29747993/long-term-effect-of-b-cells-depletion-alone-as-rescue-therapy-for-severe-thrombocytopenia-in-primary-antiphospholipid-syndrome
#3
Savino Sciascia, Massimo Radin, Irene Cecchi, Elena Rubini, Mario Bazzan, Dario Roccatello
OBJECTIVES: To investigate the long-term effect of B-cell depletion therapy with Rituximab (RTX) alone as rescue therapy in primary antiphospholipid syndrome (PAPS) patients with severe thrombocytopenia. METHODS: We retrospectively retrieved data from patients who met the following inclusion criteria: (a) persistent antiphospholipid antibodies (aPL) positivity and fulfilled the Sydney criteria for PAPS (b) presented with severe thrombocytopenia (platelets <50,000/mm3 ) (c) were treated with RTX as a rescue therapy (d) had at least 1 year of follow-up after B-cells depletion therapy...
April 11, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29735172/comment-on-efficacy-of-curcumin-and-boswellia-for-knee-osteoarthritis-systematic-review-and-meta-analysis
#4
LETTER
Ali Mobasheri, Yves Henrotin
No abstract text is available yet for this article.
April 11, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29706243/practical-suggestions-on-intravenous-iloprost-in-raynaud-s-phenomenon-and-digital-ulcer-secondary-to-systemic-sclerosis-systematic-literature-review-and-expert-consensus
#5
REVIEW
Francesca Ingegnoli, Tommaso Schioppo, Yannick Allanore, Roberto Caporali, Michele Colaci, Oliver Distler, Daniel E Furst, Nicolas Hunzelmann, Florenzo Iannone, Dinesh Khanna, Marco Matucci-Cerinic
BACKGROUND: Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud's phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainly on the European market approved for RP secondary to SSc with 3-5 days infusion cycle...
April 4, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29609799/diagnostic-value-of-screening-enzyme-immunoassays-compared-to-indirect-immunofluorescence-for-anti-nuclear-antibodies-in-patients-with-systemic-rheumatic-diseases-a-systematic-review-and-meta-analysis
#6
REVIEW
Seri Jeong, Dahae Yang, Woonhyoung Lee, Geun-Tae Kim, Hyon-Suk Kim, Hyeong Sik Ahn, Hyun Jung Kim
OBJECTIVE: This study aimed to review and compare the diagnostic accuracy of the screening enzyme immunoassay (SEIA) and indirect immunofluorescence (IIF) as anti-nuclear antibody (ANA) screening assays for patients with systemic rheumatic diseases (SRDs), including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), and systemic sclerosis (SSc). METHODS: A systematic literature search was conducted in the Medline, Embase, Cochrane, Web of Science, and Scopus databases for articles published before August 2017...
March 30, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29735171/high-rates-of-tuberculin-skin-test-positivity-due-to-methotrexate-therapy-false-positive-results
#7
Miguel Arias-Guillén, Marta M Sánchez Menéndez, Mercedes Alperi, Sabino Riestra-Menéndez, María Teresa González Budiño, Marta María García-Clemente, Susana Martínez-González, Ana Isabel Enríquez, Rebeca Alonso-Arias, Juan José Palacios Gutiérrez, Miguel Santibáñez, Pablo Coto-Segura, Pablo Martínez Camblor, Lucía García-Alfonso, Isla Morante, Patricio Escalante
RATIONALE: The tuberculin skin test (TST) and interferon γ release assays (IGRAs) are commonly used for latent tuberculosis infection (LTBI) screening. Unexpectedly high TST positivity rates have been reported in patients with rheumatic diseases, and methotrexate is frequently used in this population. We hypothesized that methotrexate use could be associated with false-positive TST results. OBJECTIVES: To investigate whether treatment with methotrexate and other factors are associated with false-positive TST results in patients with rheumatic diseases...
March 29, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29773230/medications-received-by-patients-with-juvenile-dermatomyositis
#8
Takayuki Kishi, Nastaran Bayat, Michael M Ward, Adam M Huber, Lan Wu, Gulnara Mamyrova, Ira N Targoff, William J Warren-Hicks, Frederick W Miller, Lisa G Rider
OBJECTIVE: Few controlled studies are available to guide treatment decisions in juvenile dermatomyositis (JDM). This study evaluated therapies received, changes of treatment over time, and factors associated with medication choices in JDM. METHODS: We performed a retrospective analysis of the number and type of therapies and duration of treatment for 320 patients with JDM enrolled in a North American registry. Kaplan-Meier and logistic regression analysis were used to assess the association of demographic and clinical features and autoantibodies with medication usage...
March 28, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29706241/the-nomenclature-of-the-basic-disease-elements-of-gout-a-content-analysis-of-contemporary-medical-journals
#9
David Bursill, William J Taylor, Robert Terkeltaub, Nicola Dalbeth
OBJECTIVES: There is currently no standardised nomenclature for the basic disease elements of gout. This study aimed to identify these elements and examine how they are labelled in contemporary medical literature. METHODS: We analysed articles from the ten highest ranked general rheumatology journals, and five highest ranked general internal medicine journals (by Impact Factor, according to 2015 Thomson-Reuters Journal Citation Reports), published between 1 January 2012 and 31 January 2017...
March 28, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29685483/comment-on-inflammatory-myopathy-associated-with-anti-mitochondrial-antibodies-a-distinct-phenotype-with-cardiac-involvement
#10
LETTER
Angela Ceribelli, Natasa Isailovic, Maria De Santis, Carlo Selmi
No abstract text is available yet for this article.
March 28, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29706242/diagnostic-utility-of-automated-indirect-immunofluorescence-compared-to-manual-indirect-immunofluorescence-for-anti-nuclear-antibodies-in-patients-with-systemic-rheumatic-diseases-a-systematic-review-and-meta-analysis
#11
REVIEW
Jinmi Kim, Woonhyoung Lee, Geun-Tae Kim, Hyon-Suk Kim, Soyoung Ock, In-Soo Kim, Seri Jeong
OBJECTIVE: This study aimed to review and compare the analytical and clinical performance of automated indirect immunofluorescence (AIIF) and manual indirect immunofluorescence (MIIF) as anti-nuclear antibody screening assays for patients with systemic rheumatic diseases (SRDs), such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). METHODS: A systematic literature search was performed in the Medline, Embase, Cochrane, Web of Science, and Scopus databases for studies published before August 2017...
March 27, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29685482/patient-acceptable-symptom-state-and-minimal-clinically-important-difference-for-patient-reported-outcomes-in-systemic-sclerosis-a-secondary-analysis-of-a-randomized-controlled-trial-comparing-personalized-physical-therapy-to-usual-care
#12
Camille Daste, François Rannou, Luc Mouthon, Katherine Sanchez, Alexandra Roren, Vincent Tiffreau, Éric Hachulla, Philippe Thoumie, Jean Cabane, Emmanuel Chatelus, Jean Sibilia, Serge Poiraudeau, Christelle Nguyen
BACKGROUND: To estimate patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) for patient-reported outcomes in systemic sclerosis (SSc). METHODS: We conducted a secondary analysis of the SCLEREDUC trial, a 12-month randomized controlled trial comparing the efficacy of physical therapy to usual care in 220 SSc patients followed-up from September 2005 to October 2010. Self-rated state and change in patient health at 12 months were assessed by using 2 external anchors extracted from the Medical Outcomes Study 36-Item Short-Form...
March 27, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29602559/predictive-value-of-early-structural-changes-on-radiographs-and-mri-for-incident-clinical-and-radiographic-knee-osteoarthritis-in-overweight-and-obese-women
#13
Claudia Bernadette Maria Bijen, Jos Runhaar, Joanne Bernadine Marie Rijkels-Otters, Edwin Hong Gwan Oei, Sebastia Margaretha Agatha Bierma-Zeinstra
OBJECTIVE: To determine the predictive value of tibiofemoral (TF), patellofemoral (PF) MRI osteoarthritis (OA), and Kellgren and Lawrence grade 1 (KLG1) for the incidence of knee OA (clinical and/or radiological signs) at 2.5 and 6.5 years follow-up in a high-risk cohort. METHODS: Data of the PROOF study were used, consisting of middle-aged obese women without clinical (ACR-criteria) knee OA and free of radiographic signs (KLG < 2) at baseline. To determine the relation between MRI defined knee OA and KLG1 at baseline with clinical (ACR criteria) or radiographic OA (KLG ≥ 2) at the follow-up points, sensitivity, specificity, likelihood ratios and pre-test and post-test probabilities were calculated...
March 27, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29673963/no-difference-in-cardiovascular-risk-of-tocilizumab-versus-abatacept-for-rheumatoid-arthritis-a-multi-database-cohort-study
#14
Seoyoung C Kim, Daniel H Solomon, James R Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss
OBJECTIVES: While tocilizumab may increase serum lipid levels, recent studies do not suggest a link between tocilizumab use and clinical cardiovascular risk in patients with rheumatoid arthritis (RA). METHODS: To compare cardiovascular safety of tocilizumab with abatacept, we conducted a cohort study using data from Medicare (2010-2013), IMS PharMetrics (2011-2014) and MarketScan (2011-6/2015). RA patients aged ≥18 years who newly started tocilizumab or abatacept entered the cohort on the day of their first use of tocilizumab or abatacept after a continuous enrollment period for ≥365 days...
March 22, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29747994/a-systematic-review-of-viral-exposures-as-a-risk-for-rheumatoid-arthritis
#15
F M Kudaeva, M R Speechley, J E Pope
OBJECTIVE: Different viral exposures have been implicated in the etiology of rheumatoid arthritis (RA). Evidence relating to the association between putative viral exposures and the development of RA was reviewed. METHODS: A systematic literature search was conducted using MEDLINE-OVID, EMBASE-OVID, PUBMED and Cochrane library databases. Articles were included if they were case-controls, cross-sectional or cohort studies and were published in English. Case-series were included if there was a lack of other study designs...
March 21, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29573850/clinical-presentation-of-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-differs-by-immunotherapy-regimen
#16
Laura C Cappelli, Julie R Brahmer, Patrick M Forde, Dung T Le, Evan J Lipson, Jarushka Naidoo, Lei Zheng, Clifton O Bingham, Ami A Shah
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. METHODS: Patients with rheumatologist-confirmed IA occurring during or after ICI treatment with no prior history of autoimmune disease were included...
March 21, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29573848/measurement-properties-of-patient-reported-outcome-measures-for-spondyloarthritis-a-systematic-review
#17
REVIEW
Kelly Png, Yu Heng Kwan, Ying Ying Leung, Jie Kie Phang, Jia Qi Lau, Ka Keat Lim, Eng Hui Chew, Lian Leng Low, Chuen Seng Tan, Julian Thumboo, Warren Fong, Truls Østbye
OBJECTIVES: This systematic review aimed to identify studies investigating measurement properties of patient reported outcome measures (PROMs) for spondyloarthritis (SpA), and to evaluate their methodological quality and level of evidence relating to the measurement properties of PROMs. METHODS: This systematic review was guided by the preferred reporting items for systematic review and meta-analysis (PRISMA). Articles published before 30 June 2017 were retrieved from PubMed® , Embase® , and PsychINFO® (Ovid)...
March 21, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29751976/high-prevalence-of-hidradenitis-suppurativa-symptoms-in-axial-spondyloarthritis-patients-a-possible-new-extra-articular-manifestation
#18
Angelique Rondags, Suzanne Arends, Freke R Wink, Barbara Horváth, Anneke Spoorenberg
BACKGROUND: Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α. Recently, SpA was reported to be more prevalent (2.3-28.2%) in patients with HS than in the general population. Conversely, the prevalence of HS in SpA is not exactly known...
March 20, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29656791/cardiovascular-risk-factors-predicting-cardiac-events-are-different-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis
#19
Roxanne Cooksey, Sinead Brophy, Jonathan Kennedy, Fabiola Fernandez Gutierrez, Tim Pickles, Ruth Davies, Vincent Piguet, Ernest Choy
OBJECTIVES: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in psoriatic arthritis (PsA) and RA...
March 17, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29650240/serum-bisphenol-a-is-an-independent-risk-factor-of-hyperuricemia-a-6-year-prospective-study
#20
Jinbo Hu, Chuan Peng, Jiayu Li, Rufei Gao, Aipin Zhang, Linqiang Ma, Linkun Zhang, Yi Yang, Qingfeng Cheng, Yue Wang, Ting Luo, Zhihong Wang, Hua Qing, Shumin Yang, Qifu Li
OBJECTIVE: This study aims to evaluate whether serum Bisphenol A (BPA) is a risk factor for hyperuricemia. METHODS: In this prospective study, a total of 482 participants without hyperuricemia were enrolled at baseline and followed up for 6 years. Clinical characteristics were recorded, and serum levels of uric acid and BPA were measured. Participants were stratified into tertiles according to low, median, and high baseline serum BPA levels. Regression models were used to analyze associations of serum BPA with the change in uric acid and the risk of developing hyperuricemia...
March 17, 2018: Seminars in Arthritis and Rheumatism
journal
journal
25454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"